Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIJEX vs NALBUPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Management of secondary hyperparathyroidism in patients with chronic kidney disease stage 3, 4, and 5 on dialysis,Hypocalcemia in patients with hypoparathyroidism,Hypocalcemia in renal osteodystrophy,Off-label: treatment of hypocalcemia due to pseudohypoparathyroidism or vitamin D-dependent rickets
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Primarily hepatic via 24-hydroxylation; also undergoes further oxidation and conjugation. Not significantly metabolized by CYP450 enzymes.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Approximately 99.9% bound to vitamin D-binding protein (DBP) and albumin.
Approximately 50% bound to plasma proteins, primarily albumin.
Volume of distribution (Vd) is approximately 0.25 L/kg (range 0.2-0.3 L/kg). This low Vd indicates distribution mainly to extracellular fluid and tissues.
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Oral bioavailability is approximately 60-70% when administered as the injectable formulation orally; however, for IV administration, bioavailability is 100%.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
For GFR < 30 m L/min: reduce initial dose to 0.25 mcg oral or 0.5 mcg IV three times weekly. No adjustment for GFR > 30 m L/min.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
No specific recommendations for Child-Pugh classes; caution in severe hepatic impairment due to risk of accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Intravenous: 0.01-0.05 mcg/kg three times weekly; titrate based on calcium and PTH levels. Oral: 0.015-0.025 mcg/kg once daily.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Start at low end of dosing range (0.25 mcg oral or 0.25-0.5 mcg IV three times weekly); monitor calcium and phosphate closely due to increased sensitivity.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
None
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hypercalcemia, hypercalciuria, hyperphosphatemia; aluminum hydroxide use may increase aluminum absorption; avoid vitamin D supplementation; monitor serum calcium and phosphate levels regularly; caution in patients with coronary artery disease (calcium load).
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Hypercalcemia, vitamin D toxicity, known hypersensitivity to calcitriol or any component of the formulation.
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Avoid excessive dietary calcium (dairy products, fortified foods) during treatment. Do not take calcium-containing antacids or supplements. Maintain adequate fluid intake to prevent hypercalcemia.
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data are limited. Pregnancy Category C. First trimester: Theoretical risk of teratogenicity if hypercalcemia occurs; avoid excessive doses. Second and third trimesters: Risk of fetal hypercalcemia and suppression of parathyroid function if maternal hypercalcemia develops; use only if clearly needed and monitor maternal calcium levels.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Calcitriol is excreted into human breast milk but in low amounts. No adverse effects reported in nursing infants. The M/P ratio is not established. Caution is advised due to risk of hypercalcemia in the infant; monitor infant serum calcium if maternal use is necessary.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
Dosing adjustments may be required due to altered calcium metabolism in pregnancy. Increase in glomerular filtration rate (GFR) and expanded plasma volume may increase clearance, potentially requiring higher doses. However, maintain normocalcemia; monitor serum calcium and adjust dose accordingly. Starting dose typically unchanged but may need titration based on calcium levels.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
Monitor serum calcium and phosphate levels closely; hypercalcemia risk is highest with concurrent thiazide use or high calcium intake. Adjust dose based on PTH levels in CKD patients. Use with caution in digitalis-treated patients due to additive positive inotropic effect.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Take this medication exactly as prescribed; do not change dose or frequency without consulting your doctor.,Alert your doctor if you experience symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid excessive intake of calcium-rich foods, supplements, or antacids during treatment.,You may need regular blood tests to monitor calcium, phosphate, and parathyroid hormone levels.,Inform all healthcare providers that you are taking Calcijex.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
No interactions on record
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIJEX vs NALBUPHINE, answered by our medical review team.
CALCIJEX is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.. NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIJEX and NALBUPHINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIJEX is: Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.. The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIJEX and NALBUPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIJEX is classified as Category C. Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data a. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.